Erwiderung

Ohne Zusammenfassung     

Pirbuterol in the treatment of bronchial asthma.

Pirbuterol, a new anti-asthmatic compound, was tested in 21 male outpatients with reversible bronchospastic disease during 12 months in different dosis regimens in order to determine the extent and duration of bronchodilator activity, the optimum multiple dose-schedule, the incidence, type and degree of side effects, and the cardiovascular as well as hematologic, renal and hepatic function after oral administration. All patients were checked by monthly pulmonary function studies, E.C.G. and extensive laboratory tests. Aso slit lamp examinations were performed. Pirbuterol is a well-tolerated bronchodilator which appears to be of clinical importance in the long-term treatment of bronchospastic disease.     

Magnetic resonance imaging: absence of in vitro cytogenetic damage

Human lymphocytes and Chinese hamster ovary (CHO) cells in culture were exposed for 12 1/2 hours to a magnetic resonance imaging apparatus with a 2.35-Tesla magnet and 100-MHz radio frequency emission. The cells were examined for cytogenetic damage manifested either as chromosome aberrations or sister chromatid exchanges (SCEs), which constitute very sensitive measures of genetic and cellular damage. In either unstimulated or stimulated human lymphocytes, as well as in exponentially growing CHO cells, no increase in either chromosome aberrations or SCEs was found as a result of exposure to these MR conditions. The data indicate that long-term exposure to MR imaging conditions far exceeding those to be found in the clinical situation does not cause cytogenetic damage.